Agenus to Present Colorectal Cancer Data at SITC 2026

Agenus Inc. announced that two posters highlighting research on botensilimab (BOT) in combination with balstilimab (BAL) have been accepted for presentation at SITC 2026. The presentations will cover long-term survival data for BOT+BAL and translational research with agenT-797 in colorectal cancer.